Effects of Olmesartan Medoxomil Angiotensin Type 1 (AT1) Receptor Blocker 1 in Selected Patients with Nonalcoholic Steatohepatitis (NASH): Pilot Study
Not Applicable
- Conditions
- Patients with nonalcoholic steatohepatitis (NASH)
- Registration Number
- JPRN-UMIN000005409
- Lead Sponsor
- Kitasato University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Mean arterial pressure is less than 60 mmHg. (2)ARB intolerance. (3)Current treatment with ARB, angiotensin-converting enzyme inhibitors, or beta blockers. (4)Hypertrophic cardiomyopathy or renal arterial stenosis. (5)Serum creatinine is more than 1.6 mg/dL. (6)Hyperkalemia defined as plasma potassium more than 5.5 meq/L. (7)Hepatocellular carcinoma. (8)Portal venous tumor thrombosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of liver fibrosis marker
- Secondary Outcome Measures
Name Time Method